Oncology | Phase I Developments | FRANCE

Transgene

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Transgene Presents Promising New Data from its Next-Generation Immunotherapy Platforms at AACR 2020

Lead Product(s): TG4050

Therapeutic Area: Oncology Product Name: TG4050

Highest Development Status: Phase I Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 22, 2020

Details:

Transgene presents data demonstrating that the prediction algorithm used to customize TG4050 for each patient is accurate at identifying immunogenic cancer mutations even among a large set of candidate tumor mutations.

Nanobiotix

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Nanobiotix Announces Positive First Results From Phase I Expansion in Locally Advanced Head and Neck Cancer at ASCO 2020

Lead Product(s): Hafnium dioxide,Cisplatin

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 29, 2020

Details:

NBTXR3 has been administered to 40 patients in the trial and was well tolerated, maintaining the safety profile observed in the dose escalation part of the phase I study.

MaaT Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

MaaT Pharma Announces Formation of Its GvHD-focused Scientific Advisory Board

Lead Product(s): MaaT033

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 12, 2020

Details:

SAB will serve as an advisor to MaaT Pharma on its scientific, regulatory and clinical development strategies supporting the further clinical evaluation of its microbiome restoration biotherapeutics.

Nanobiotix

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

NANOBIOTIX Announces First Phase I Trial With NBTXR3 in Pancreatic Cancer Is Safe to Proceed Per US FDA

Lead Product(s): Hafnium dioxide

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 07, 2020

Details:

The trial is a phase I dose escalation study evaluating the safety & feasibility of NBTXR3 activated by radiation therapy in locally advanced or borderline-resectable pancreatic ductal adenocarcinoma.

Ipsen

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

MD Anderson and Ipsen Advance New Therapy with Potential Benefit for Underserved Patients with Lung and Ovarian Cancers

Lead Product(s): IPN60090,Pembrolizumab,Paclitaxel

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 27, 2020

Details:

IPN60090, now under investigation in a Phase I trial, may hold benefit for certain patients with lung and ovarian cancers.

Innate Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

France France

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

First patient dosed in IPH5201 Phase I clinical trial in advanced solid tumors

Lead Product(s): IPH5201

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 10, 2020

Details:

Anti-CD39 monoclonal antibody, IPH5201, advances to first-in-human clinical trial; first molecule from Innate/AstraZeneca expanded collaboration progressing to the clinic.

Cellectis

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Cellectis and Servier Execute the Amendment Confirming the Expansion of Their Collaboration on UCART19 Products

Lead Product(s): UCART19

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Servier Canada

Deal Size: $410.0 million Upfront Cash: $27.6 million

Deal Type: Agreement March 04, 2020

Details:

Cellectis grants to Servier an expanded exclusive worldwide license to develop and commercialize all next generation gene-edited allogeneic CAR T-cell products targeting CD19.

Cellectis

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Cellectis and Servier Expand Collaboration on UCART19 Products

Lead Product(s): UCART19

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Laboratoires Servier

Deal Size: $437.6 million Upfront Cash: $27.6 million

Deal Type: Agreement February 18, 2020

Details:

Cellectis shall grant to Servier, an expanded exclusive worldwide license to develop and commercialize all next generation gene-edited allogeneic CAR T-cell products, including rights to ALLO-501A.

Nanobiotix

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

NANOBIOTIX Gets Fast Track Designation By U.S. FDA NBTXR3

Lead Product(s): Hafnium dioxide

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 10, 2020

Details:

The U.S. FDA concluded that investigation of NBTXR3 activated by radiation therapy, with or without cetuximab, meets the criteria for a Fast Track development program.

Cellectis

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

First Patient Dosed with Cellectis’ New Allogeneic UCART123 Product Candidate for Relapsed/Refractory Acute Myeloid Leukemia

Lead Product(s): UCART123

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 15, 2020

Details:

AMELI-01 clinical trial uses new UCART123 construct with optimized production process & new IND number.

Find

Find Oncology Drugs in Phase I Clinical Development in FRANCE

France

Product Type

Companies

Transgene

Transgene Presents Promising New Data from its Next-Generation Immunotherapy Platforms at AACR 2020

Nanobiotix

Nanobiotix Announces Positive First Results From Phase I Expansion in Locally Advanced Head and Neck Cancer at ASCO 2020

MaaT Pharma

MaaT Pharma Announces Formation of Its GvHD-focused Scientific Advisory Board

Nanobiotix

NANOBIOTIX Announces First Phase I Trial With NBTXR3 in Pancreatic Cancer Is Safe to Proceed Per US FDA

Ipsen

MD Anderson and Ipsen Advance New Therapy with Potential Benefit for Underserved Patients with Lung and Ovarian Cancers

Innate Pharma

First patient dosed in IPH5201 Phase I clinical trial in advanced solid tumors

Cellectis

Cellectis and Servier Execute the Amendment Confirming the Expansion of Their Collaboration on UCART19 Products

Cellectis

Cellectis and Servier Expand Collaboration on UCART19 Products

Nanobiotix

NANOBIOTIX Gets Fast Track Designation By U.S. FDA NBTXR3

Cellectis

First Patient Dosed with Cellectis’ New Allogeneic UCART123 Product Candidate for Relapsed/Refractory Acute Myeloid Leukemia